| Document |
Document Title |
|
WO/2017/143237A1 |
Provided herein is a combination comprising an HDAC inhibitor and an IMiD for increasing interferon regulated gene expression or decreasing c-MYC gene expression in a cancer cell or tumor in a subject in need thereof. Increasing interfer...
|
|
WO/2017/140612A1 |
The invention relates to quinazolinedione-6-carbonyl derivatives of general formula (I) used as herbicides. In formula (I), R1, R2, X and W stand for groups such as hydrogen, alkyl and halogen. Z is a chalcogen. Q is a five-membered hete...
|
|
WO/2017/133283A1 |
A composite catalyst, prepared by combining a compound A or/and salts thereof with a metallic compound W, wherein the compound A has a structure illustrated by general formula I: in general formula I, R1, R3, R5, and R6 each independentl...
|
|
WO/2017/135472A1 |
Provided is a compound having an integrin α4 inhibiting action. A sulfonamide derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof. (In the formula, R1-R5, e-h, D, and B are as defined in the speci...
|
|
WO/2017/135471A1 |
Provided is a compound having an excellent integrin α4 inhibiting action. A sulfonamide derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof. (In the formula, R1-R5, e-h, D, and B are as defined in...
|
|
WO/2017/134188A1 |
The present invention is directed to novel compounds of Formula I; pharmaceutically acceptable salts or solvates thereof, and their use.
|
|
WO/2017/131221A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions cont...
|
|
WO/2017/129796A1 |
The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.
|
|
WO/2017/131171A1 |
Provided is a compound represented by general formula (I) and a pharmaceutically acceptable salt thereof. [In formula (I): A1 is a methylene group, and the like; A2 is a methylene group or an oxygen atom; A3 is an azetidinyl group, pyrro...
|
|
WO/2017/128036A1 |
Disclosed are a new class of quinazoline-2,4 (1H, 3H)-diketone PARP-1 inhibitors, and a preparation method and pharmaceutical composition and a use thereof. In particular, the present invention relates to a quinazoline-2,4 (1H, 3H)-diket...
|
|
WO/2017/130221A1 |
The present invention provides an improved process for the preparation of compound of formula III by cyclizing compound of formula II in presence of hexamethyldisilazane and a base in a solvent. The compound of formula III is further con...
|
|
WO/2017/126818A1 |
Disclosed are a compound represented by chemical formula 1, an organic electronic element comprising a first electrode, a second electrode, and an organic layer between the first electrode and the second layer, and an electronic device c...
|
|
WO/2017/122205A1 |
Radiolabeled compounds which are erlotinib analogs that feature a radioactive halogen and processes of preparing same are disclosed. Uses of these radiolabeled compounds in radioimaging, for identifying and monitoring a level, distributi...
|
|
WO/2017/123823A1 |
This application discloses compounds and pharmaceutical compositions and methods of using the same for inhibition of sulfide:quinone oxidoreductase (SQOR).
|
|
WO/2017/118438A1 |
The present invention provides a heterocyclic compound used as a fibroblast growth factor receptor (FGFR) inhibitor. Specifically, the present invention provides a compound represented by formula (I), comprising an isomer (an enantiomer ...
|
|
WO/2017/117680A1 |
A novel class of fluorinated derivatives of Formula (I) have been prepared and found to be useful in the treatment of cancers and other EGFR related disorders. (I)
|
|
WO/2017/118822A2 |
The present invention relates to the design of new molecules, referred to as "multi-target" molecules, having a double pharmacophore and acting both as inhibitors of histone deacetylases (HDAC) and as inhibitors of tubulin polymerisation...
|
|
WO/2017/120575A1 |
The disclosure provides compounds of the formula I and the pharmaceutically acceptable salts thereof. The variables, e.g. R1, R2, R3, R4, A, B, J, V, W, M, J and Ar are defined herein. The disclosure also provides pharmaceutical composit...
|
|
WO/2017/117538A1 |
The present disclosure provides pharmaceutical agents of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Method...
|
|
WO/2017/114052A1 |
Disclosed are a high stress resistant plant growth regulator and a preparation method and use thereof. In particular, the compound provided by the present invention is an ABA substitute for significantly improving the stress resistance o...
|
|
WO/2017/117535A1 |
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula (I) or their pharmaceutically acceptable salts, and methods of using...
|
|
WO/2017/114500A1 |
Disclosed in the present invention are an acrylanilide compound represented by general formula (I) and a pharmaceutically acceptable salt thereof. The acrylanilide compound and the pharmaceutically acceptable salt thereof are used for tr...
|
|
WO/2017/114735A1 |
The present invention relates to a process for preparation of crystalline Form 1 of gefitinib of formula (1) characterized by a XRPD powder diffraction pattern comprising, inter alia, peaks at about 7.14, 11.26, 14.25, 15.86, 24.33 and 2...
|
|
WO/2017/112823A1 |
The invention relates to methods to select patients for treatment with specific Cortistatin analogs.
|
|
WO/2017/112777A1 |
Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are compositions and methods for treating cancer and inflammatory disease.
|
|
WO/2017/112678A1 |
Disclosed herein; are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs...
|
|
WO/2017/108656A1 |
The invention relates to compounds of general formula (I), to the agrochemically compatible salts thereof and to the use thereof in the field of plant protection.
|
|
WO/2017/106556A1 |
Compounds having the following formula (I) and methods of their use and preparation are disclosed.
|
|
WO/2017/105090A1 |
The present invention provides the Form 1 crystalline polymorph of L-carnitine orotate, a production method therefor, and a use thereof. The Form 1 crystalline polymorph of L-carnitine orotate of the present invention can be used as a ph...
|
|
WO/2017/106639A1 |
The present application relates to methods of preparing Compound A: or a salt thereof, and a polymorph of Compound A dihydrochloride salt.
|
|
WO/2017/102014A1 |
The present invention deals with new flavivirus inhibitors, compositions comprising said inhibitors and methods for the treatment of disorders related to a viral infection, such as a disease due to a flavivirus infection, comprising admi...
|
|
WO/2017/101803A1 |
The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of...
|
|
WO/2017/106634A1 |
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...
|
|
WO/2017/106642A1 |
The present application provides solid forms of (R)-6-(2-fluorophenyl)-N-(3-(2-(2- methoxyethylamino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazoli
n-2-amine dihydrochloride, and methods of preparing and using same.
|
|
WO/2017/100591A1 |
Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compou...
|
|
WO/2017/098440A1 |
The present invention relates to LpxC antibacterial compounds of Formula (1A), corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions:, compound preparation, treatment methods and uses for bact...
|
|
WO/2017/096484A1 |
This present disclosure relates to the use of a cranberry extract rich in proanthocyanidins as antibiotic synergizing agent to mitigate multidrug resistance and biofilm formation in different pathogenic bacteria. The synergistic combinat...
|
|
WO/2017/079670A9 |
Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the lysine specific demethylase-1 inhibitor 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-
1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-...
|
|
WO/2017/097113A1 |
The present invention relates to aminopyrimidine compounds capable of inhibiting the activity of protein tyrosine kinase, and to preparation and uses thereof. Specifically, disclosed are an aminopyrimidine compound shown in Formula (I), ...
|
|
WO/2017/092413A1 |
Provided are diaminopyrimidine compounds as shown in formula (I), and a pharmaceutical composition comprising the compounds or a crystal form, a pharmaceutically acceptable salt, a hydrate or solvate, a stereoisomer, a prodrug or an isot...
|
|
WO/2017/092977A1 |
The present invention relates to a novel method for preparing enantiomerically pure N-(pyridin-4-yl)-2-hydroxy-alkylamide compounds having the following general formula (C): and to the methods for preparing reaction intermediates used in...
|
|
WO/2017/093903A1 |
The present invention relates to an improved process for the preparation of macitentan and pharmaceutical acceptable salts thereof. Further present invention also relates to methylene chloride solvate of macitentan and their use in the p...
|
|
WO/2017/095758A1 |
In its many embodiments, the present invention provides certain substituted bispiperidinyl compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein ring A, ring B, R1, R2, R3, L, R4, X, Z, Li, Q and R5 are as ...
|
|
WO/2017/092477A1 |
A crystalline form of mesosulfuron-methyl of formula (I), the crystal preparation process, the analyses of the crystal through various analytical methods and using the crystal to prepare stable agrochemical formulation are described. The...
|
|
WO/2017/096130A1 |
The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
|
|
WO/2017/091661A1 |
The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to...
|
|
WO/2017/091836A1 |
The present invention provides a method for enhancing the efficacy of AraC in the treatment of hematological malignancies, comprising inhibiting CDK8/19 in a hematological cancer cell in combination with contacting the cell with AraC.
|
|
WO/2017/091453A1 |
Disclosed herein is a novel process for preparing substituted quinazoline compounds of formula (I) using a hydrogen bonding catalyst.
|
|
WO/2017/087818A1 |
Dual Src/p38 kinase inhibitor compounds and compositions comprising the same are disclosed. Methods of using the compounds in the treatment of hyperproliferative disease such as cancer are also disclosed.
|
|
WO/2017/087608A1 |
Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical...
|
